title: Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial.
abstract: We report the results of a randomized, double-blind, placebo-controlled exploratory trial of the chimeric monoclonal anti-CD4 antibody cM-T412 in 71 patients suffering from active relapsing-remitting and secondary progressive multiple sclerosis. Infusion of the antibody produced frequent but usually minor side effects and resulted in a long-lasting reduction of circulating CD4-positive T cells. There was no significant effect on the primary measure of efficacy, the number of active lesions on monthly gadolinium-enhanced MRI over 9 months. Further statistical evaluation provided evidence that the degree of depletion of CD4-positive cells was important with regard to treatment efficacy; using CD4 counts as a covariate there was a statistically significant effect on the number of active lesions over 18 months (p = 0.04). There was a statistically significant reduction of 41% in the number of clinical relapses (a secondary efficacy parameter) after 9 months (p = 0.02), which was still present after 18 months, but this finding may be partly due to physician unblinding. Other secondary efficacy parameters (Expanded Disability Status Scale progression, number of courses of methylprednisolone) were not influenced by anti-CD4 treatment. We conclude that intravenous treatment with the monoclonal antibody cM-T412 in the dosage we used results in a substantial and sustained reduction of the number of circulating CD4-positive cells, but is not able to reduce MS activity as measured by monthly gadolinium-enhanced MRI, and is therefore unlikely to have a beneficial effect on the clinical disease course. We found preliminary evidence suggesting that more aggressive depletion of CD4-positive cells might lead to a more substantial reduction in MRI activity.
authors.affiliation: Department of Neurology, Free University Hospital, Amsterdam, The Netherlands.
authors.forename: B W
authors.initials: BW
authors.lastname: van Oosten
authors.forename: M
authors.initials: M
authors.lastname: Lai
authors.forename: S
authors.initials: S
authors.lastname: Hodgkinson
authors.forename: F
authors.initials: F
authors.lastname: Barkhof
authors.forename: D H
authors.initials: DH
authors.lastname: Miller
authors.forename: I F
authors.initials: IF
authors.lastname: Moseley
authors.forename: A J
authors.initials: AJ
authors.lastname: Thompson
authors.forename: P
authors.initials: P
authors.lastname: Rudge
authors.forename: A
authors.initials: A
authors.lastname: McDougall
authors.forename: J G
authors.initials: JG
authors.lastname: McLeod
authors.forename: H J
authors.initials: HJ
authors.lastname: Adèr
authors.forename: C H
authors.initials: CH
authors.lastname: Polman
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D015704:CD4 Antigens / Q000276:immunology*; D018791:CD4 Lymphocyte Count; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D010919:Placebos
chemical_list: D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D010919:Placebos